Found: 8
Select item for more details and to access through your institution.
Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma.
- Published in:
- Journal of Asthma & Allergy, 2008, v. 1, p. 31
- By:
- Publication type:
- Article
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
- Published in:
- Oncogene, 2004, v. 23, n. 54, p. 8766, doi. 10.1038/sj.onc.1208118
- By:
- Publication type:
- Article
p38 MAPK inhibition reduces diabetes-induced impairment of wound healing.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2009, v. 2, p. 91
- By:
- Publication type:
- Article
Pharmacological Properties of SD-282 – An α-Isoform Selective Inhibitor for p38 MAP Kinase.
- Published in:
- Pharmacology, 2007, v. 81, n. 3, p. 204, doi. 10.1159/000112865
- By:
- Publication type:
- Article
Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig.
- Published in:
- Journal of Inflammation Research, 2010, v. 3, p. 9
- By:
- Publication type:
- Article
A p38 Mitogen-Activated Protein Kinase Inhibitor Arrests Active Alveolar Bone Loss in a Rat Periodontitis Model.
- Published in:
- Journal of Periodontology, 2007, v. 78, n. 10, p. 1992, doi. 10.1902/jop.2007.070101
- By:
- Publication type:
- Article
Can a Selective PPAR[gamma] Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?
- Published in:
- Diabetes Care, 2014, v. 37, n. 7, p. 1918, doi. 10.2337/dc13-2480
- By:
- Publication type:
- Article